The Full Wiki

CGMP specific phosphodiesterase type 5: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

edit
Phosphodiesterase 5A, cGMP-specific

PDB rendering based on 3BJC.
Available structures
1rkp, 1t9r, 1t9s, 1tbf, 1udt, 1udu, 1uho, 1xoz, 1xp0, 2chm, 2h40, 2h42, 2h44
Identifiers
Symbols PDE5A; CGB-PDE; CN5A; PDE5; PDE5A1
External IDs OMIM603310 MGI2651499 HomoloGene842 GeneCards: PDE5A Gene
EC number 3.1.4.17
RNA expression pattern
PBB GE PDE5A 206757 at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez 8654 242202
Ensembl ENSG00000138735 ENSMUSG00000053965
UniProt O76074 Q0VBW0
RefSeq (mRNA) NM_001083 XM_001001000
RefSeq (protein) NP_001074 XP_001001000
Location (UCSC) Chr 4:
120.64 - 120.77 Mb
Chr 3:
122.72 - 122.85 Mb
PubMed search [1] [2]

cGMP-specific phosphodiesterase type 5 is an enzyme (EC 3.1.4.17) from the phosphodiesterase class. It is found in various tissues, most prominently the corpus cavernosum and the retina.

The phosphodiesterase (PDE) isozymes, found in several tissues including the rod and cone photoreceptor cells of the retina, belong to a large family of cyclic nucleotide PDEs that catalyze cAMP and cGMP hydrolysis.[1][2]

The interest in PDEs as molecular targets of drug action has grown with the development of isozyme-selective PDE inhibitors that offer potent inhibition of selected isozymes without the side-effects attributed to nonselective inhibitors such as theophylline.[3][4]

Sildenafil, Vardenafil, and Tadalafil are PDE5 inhibitors that are significantly more potent and selective than zaprinast and other early PDE5 inhibitors.

Contents

Action of PDE5

PDE5 is an enzyme that accepts cGMP and breaks it down. Sildenafil, Vardenafil and tadalafil are inhibitors of this enzyme, which bind to the catalytic site of PDE5. Both inhibitors bind with high affinity and specificity, and cGMP-binding to the allosteric sites stimulates binding of PDE5 inhibitors at the catalytic site. The kinetics of inhibitor binding and inhibition of catalysis imply the existence of two PDE5 conformers, and results of native gel electrophoresis reveal that PDE5 exists in two apparently distinct conformations, i.e., an extended conformer and a more compact conformer.

PDE5 activity is modulated by a rapidly reversible redox switch. Chemical reduction of PDE5 relieves autoinhibition of enzyme functions; allosteric cGMP-binding activity is increased 10-fold, and catalytic activity is increased ~3-fold. The redox effect on allosteric cGMP-binding occurs in the isolated regulatory domain. A change in the state of reduction of PDE5 or the isolated regulatory domain is associated with an apparent conformational change similar to that caused by phosphorylation.

PDE5 is expressed in human colonic cells and in intestinal tissue and its activity is regulated by intracellular cGMP levels in these cells that increase on GCC activation. This presumably occurs through binding of cGMP to the GAF domains in the N-terminus of PDE5, resulting in allosteric activation of the enzyme.

The mechanism of action of E4021 on both the nonactivated and activated forms of rod PDE6 because both states are relevant to understanding how PDE5-selective inhibitors may alter signal transduction pathways in photoreceptor cells. PDE5-selective inhibitors may show good discrimination of PDE5 from most other PDE isoforms.

In addition to human corpus cavernosum smooth muscle, PDE5 is also found in lower concentrations in other tissues including platelets, vascular and visceral smooth muscle, and skeletal muscle. The inhibition of PDE5 in these tissues by sildenafil may be the basis for the enhanced platelet antiaggregatory activity of nitric oxide observed in vitro, an inhibition of platelet thrombus formation in vivo and peripheral arterial-venous dilatation in vivo.

PDE5-inhibiting drugs

There are now three oral erectile dysfunction (ED) drugs: Viagra (sildenafil) by Pfizer, Levitra (vardenafil) by Bayer Pharmaceutical and Glaxo-Smith-Kline-Beecham/Schering Plough, and Cialis (tadalafil) by Lilly-ICOS.

For all practical purposes, these drugs including Viagra, Levitra, and Cialis are the first line of oral treatment for males with erectile dysfunction. In certain circumstances in which the males are young, no comorbidities are recognized, and laboratory tests are normal one should look for the etiology of their erectile dysfunction before instituting treatment since the disease process may be more serious than the symptoms, i.e., the ED itself. In some cases, treatment of the primary disease may in fact resolve the sexual dysfunction. However, most men have a cause for their ED as noted by the history and physical examination and the laboratory tests and PDE-5 inhibitors are the first line of choice.

Particular caution should be used when prescribing PDE5 inhibitors for erectile dysfunction for patients receiving protease inhibitors, including Reyataz. Coadministration of a protease inhibitor with a PDE5 inhibitor is expected to substantially increase the PDE5 inhibitor concentration and may result in an increase in PDE5 inhibitor-associated adverse events, including hypotension, visual changes, and priapism.

PDE5-inhibiting drugs are very effective. PDE5 inhibitor drugs appear to work in men regardless of why they have erectile dysfunction — including vascular disease, nerve problems, and even psychological causes. PDE5 inhibiting drugs can cause a number of minor side-effects, including headache, lightheadedness, dizziness, flushing, and change in vision.

Viagra (Sildenafil)

Discovered by Pfizer, Sildenafil is a potent and selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP in the corpus cavernosum in the penis. This means that, when sildenafil is present in the organism, normal sexual stimulation leads to increased levels of cGMP in the corpus cavernosum, which leads to better erections. Without sexual stimulation and no activation of the NO/cGMP system, sildenafil should not cause an erection.

Viagra (Sildenafil) is a member of a family of drugs called PDE5 inhibitors. Viagra was the first PDE5 inhibitor on the market. FDA approved Viagra on March 27, 1998. Viagra contains sildenafil citrate packaged as a pill.

Studies in vitro have shown that sildenafil is selective for PDE5. Its effect is more potent on PDE5 than on other known phosphodiesterases (10-fold for PDE6, >80-fold for PDE1, >700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11). The approximately 4,000-fold selectivity for PDE5 versus PDE3 is important because PDE3 is involved in control of cardiac contractility. Sildenafil is only about 10-fold as potent for PDE5 compared to PDE6, an enzyme found in the retina that is involved in the phototransduction pathway of the retina. This lower selectivity is thought to be the basis for abnormalities related to color vision observed with higher doses or plasma levels.

Levitra (vardenafil)

Levitra was the second oral PDE-5 inhibitor for erectile dysfunction to be Food and Drug Administration (FDA) approved in August 2003. In general, the feeling is that Levitra is more potent and efficient than Viagra as demonstrated by the hard-to-treat groups of patients.

Cialis (tadalafil)

Cialis has an estimated effective duration of 36 hours; however, there are studies showing high efficacy up to 100 hours.

Studies have shown that tadalafil is more selective for PDE5 over PDE6 than sildenafil or vardenafil.

See also

References

  1. ^ Uzunov P, Weiss B (1972). "Separation of multiple molecular forms of cyclic adenosine-3',5'-monophosphate phosphodiesterase in rat cerebellum by polyacrylamide gel electrophoresis". Biochim. Biophys. Acta 284 (1): 220–6. PMID 4342220.  
  2. ^ Weiss B (1975). "Differential activation and inhibition of the multiple forms of cyclic nucleotide phosphodiesterase". Adv Cyclic Nucleotide Res 5: 195–211. PMID 165666.  
  3. ^ Fertel R, Weiss B (1976). "Properties and drug responsiveness of cyclic nucleotide phosphodiesterases of rat lung" (abstract). Mol. Pharmacol. 12 (4): 678–87. PMID 183099. http://molpharm.aspetjournals.org/cgi/content/abstract/12/4/678.  
  4. ^ Weiss B, Hait WN (1977). "Selective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents". Annu. Rev. Pharmacol. Toxicol. 17: 441–77. doi:10.1146/annurev.pa.17.040177.002301. PMID 17360.  

External links


edit
Phosphodiesterase 5A, cGMP-specific
PDB rendering based on 1rkp.
Available structures: 1rkp, 1t9r, 1t9s, 1tbf, 1udt, 1udu, 1uho, 1xoz, 1xp0, 2chm, 2h40, 2h42, 2h44
Identifiers
Symbols PDE5A; CGB-PDE; CN5A; PDE5; PDE5A1
External IDs OMIM: 603310 MGI2651499 HomoloGene842
EC number 3.1.4.17
RNA expression pattern

More reference expression data

Orthologs
Human Mouse
Entrez 8654 242202
Ensembl ENSG00000138735 ENSMUSG00000053965
Uniprot O76074 Q0VBW0
Refseq NM_001083 (mRNA)
NP_001074 (protein)
XM_001001000 (mRNA)
XP_001001000 (protein)
Location Chr 4: 120.64 - 120.77 Mb Chr 3: 122.72 - 122.85 Mb
Pubmed search [1] [2]
Template:Lowercase

cGMP-specific phosphodiesterase type 5 is an enzyme (EC 3.1.4.17) from the phosphodiesterase class. It is found in various tissues, most prominently the corpus cavernosum and the retina.

The phosphodiesterase (PDE) isozymes, found in several tissues including the rod and cone photoreceptor cells of the retina, belong to a large family of cyclic nucleotide PDEs that catalyze cAMP and cGMP hydrolysis.[1][2]

The interest in PDEs as molecular targets of drug action has grown with the development of isozyme-selective PDE inhibitors that offer potent inhibition of selected isozymes without the side-effects attributed to nonselective inhibitors such as theophylline.[3][4]

Sildenafil, Vardenafil, and Tadalafil are PDE5 inhibitors which are significantly more potent and selective than zaprinast and other early PDE5 inhibitors.

Contents

Action of PDE5

PDE5 is an enzyme that accepts cGMP and breaks it down. Sildenafil and tadalafil are inhibitors of this enzyme, which bind to the catalytic site of PDE5. Both inhibitors bind with high affinity and specificity, and cGMP binding to the allosteric sites stimulates binding of PDE5 inhibitors at the catalytic site. The kinetics of inhibitor binding and inhibition of catalysis imply the existence of two PDE5 conformers, and results of native gel electrophoresis reveal that PDE5 exists in two apparently distinct conformations, i.e., an extended conformer and a more compact conformer.

PDE5 activity is modulated by a rapidly reversible redox switch. Chemical reduction of PDE5 relieves autoinhibition of enzyme functions; allosteric cGMP-binding activity is increased 10-fold, and catalytic activity is increased ~3-fold. The redox effect on allosteric cGMP-binding occurs in the isolated regulatory domain. A change in the state of reduction of PDE5 or the isolated regulatory domain is associated with an apparent conformational change similar to that caused by phosphorylation.

PDE5 is expressed in human colonic cells and in intestinal tissue and its activity is regulated by intracellular cGMP levels in these cells that increase on GCC activation. This presumably occurs through binding of cGMP to the GAF domains in the N-terminus of PDE5, resulting in allosteric activation of the enzyme.

The mechanism of action of E4021 on both the nonactivated and activated forms of rod PDE6 because both states are relevant to understanding how PDE5-selective inhibitors may alter signal transduction pathways in photoreceptor cells. PDE5-selective inhibitors may show good discrimination of PDE5 from most other PDE isoforms.

In addition to human corpus cavernosum smooth muscle, PDE5 is also found in lower concentrations in other tissues including platelets, vascular and visceral smooth muscle, and skeletal muscle. The inhibition of PDE5 in these tissues by sildenafil may be the basis for the enhanced platelet antiaggregatory activity of nitric oxide observed in vitro, an inhibition of platelet thrombus formation in vivo and peripheral arterial-venous dilatation in vivo.

PDE5-inhibiting drugs

There are now three oral erectile dysfunction (ED) drugs: Viagra (sildenafil) by Pfizer, Levitra (vardenafil) by Bayer Pharmaceutical and Glaxo-Smith-Kline-Beecham/Schering Plough, and Cialis (tadalafil) by Lilly-ICOS.

For all practical purposes, these drugs including Viagra, Levitra, and Cialis are the first line of oral treatment for males with erectile dysfunction. In certain circumstances in which the males are young, no comorbidities are recognized, and laboratory tests are normal one should look for the etiology of their erectile dysfunction before instituting treatment since the disease process may be more serious than the symptoms, i.e., the ED itself. In some cases, treatment of the primary disease may in fact resolve the sexual dysfunction. However, most men have a cause for their ED as noted by the history and physical examination and the laboratory tests and PDE-5 inhibitors are the first line of choice.

Particular caution should be used when prescribing PDE5 inhibitors for erectile dysfunction for patients receiving protease inhibitors, including Reyataz. Coadministration of a protease inhibitor with a PDE5 inhibitor is expected to substantially increase the PDE5 inhibitor concentration and may result in an increase in PDE5 inhibitor-associated adverse events, including hypotension, visual changes, and priapism.

PDE5-inhibiting drugs are very effective. PDE5 inhibitor drugs appear to work in men regardless of why they have erectile dysfunction — including vascular disease, nerve problems, and even psychological causes. PDE5 inhibiting drugs can cause a number of minor side-effects, including headache, lightheadedness, dizziness, flushing, and change in vision.

Viagra (Sildenafil)

Discovered by Pfizer, Sildenafil is a potent and selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP in the corpus cavernosum in the penis. This means that, when sildenafil is present in the organism, normal sexual stimulation leads to increased levels of cGMP in the corpus cavernosum, which leads to better erections. Without sexual stimulation and no activation of the NO/cGMP system, sildenafil should not cause an erection.

Viagra (Sildenafil) is a member of a family of drugs called PDE5 inhibitors. Viagra was the first PDE5 inhibitor on the market. FDA approved Viagra on March 27, 1998. Viagra contains sildenafil citrate packaged as a pill.

Studies in vitro have shown that sildenafil is selective for PDE5. Its effect is more potent on PDE5 than on other known phosphodiesterases (10-fold for PDE6, >80-fold for PDE1, >700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11). The approximately 4,000-fold selectivity for PDE5 versus PDE3 is important because PDE3 is involved in control of cardiac contractility. Sildenafil is only about 10-fold as potent for PDE5 compared to PDE6, an enzyme found in the retina that is involved in the phototransduction pathway of the retina. This lower selectivity is thought to be the basis for abnormalities related to color vision observed with higher doses or plasma levels.

Levitra (vardenafil)

Levitra was the second oral PDE-5 inhibitor for erectile dysfunction to be Food and Drug Administration (FDA) approved in August 2003. In general, the feeling is that Levitra is more potent and efficient than Viagra as demonstrated by the hard-to-treat groups of patients.Template:Fact

Cialis (tadalafil)

Cialis has an estimated effective duration of 36 hours; however, there are studies showing high efficacy up to 100 hours. It is not affected by any food whatsoever, and in fact can be taken with pure fat. Viagra, on the other hand, is impeded by any type of food.Template:Fact

Studies have shown that tadalafil is more selective for PDE5 over PDE6 than sildenafil or vardenafil. Template:Fact

See also

References

  1. Uzunov P, Weiss B (1972). "Separation of multiple molecular forms of cyclic adenosine-3',5'-monophosphate phosphodiesterase in rat cerebellum by polyacrylamide gel electrophoresis". Biochim. Biophys. Acta 284 (1): 220–6. PMID 4342220. 
  2. Weiss B (1975). "Differential activation and inhibition of the multiple forms of cyclic nucleotide phosphodiesterase". Adv Cyclic Nucleotide Res 5: 195–211. PMID 165666. 
  3. Fertel R, Weiss B (1976). "Properties and drug responsiveness of cyclic nucleotide phosphodiesterases of rat lung" (abstract). Mol. Pharmacol. 12 (4): 678–87. PMID 183099. http://molpharm.aspetjournals.org/cgi/content/abstract/12/4/678. 
  4. Weiss B, Hait WN (1977). "Selective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents". Annu. Rev. Pharmacol. Toxicol. 17: 441–77. doi:10.1146/annurev.pa.17.040177.002301. PMID 17360. 

External links








Got something to say? Make a comment.
Your name
Your email address
Message